Xention and Grünenthal enter Drug Discovery Collaboration in Ion Channel Research
Research collaboration to focus on development of novel pain therapeutics
Xention LTD announced that it has entered into a Research Agreement with the Grünenthal Group. Under the terms of the Agreement, Xention and Grϋnenthal will combine their respective expertise in ion channel drug discovery and pain therapy to collaborate in the identification of new drugs to treat chronic pain. Xention will apply its proprietary ion channel drug discovery platform to the design, synthesis and in vitro assessment of small molecules which target an ion channel of key pathophysiological importance in pain and against which selective ligands have not previously been developed. Grünenthal will add key expertise to all discovery aspects and assume responsibility to (pre)-clinical development and worldwide commercialization of potential new pharmaceutical products arising from the collaboration.
Grünenthal will fund the two-year research programme in its entirety, and Xention will also receive an upfront fee and be eligible for milestone fees on meeting specified discovery objectives and on the achievement of development and regulatory goals.
“We look forward to working with Xention and to accessing the wide range of ion channel drug discovery technologies Xention possesses. We anticipate that the collaboration will result in the identification of novel drugs with high clinical and commercial potential” said Prof. Eric-Paul Pâques, President Grünenthal Innovation & Chief Alliance Officer, Vice-Chairman of the Corporate Management Board of the Grünenthal Group.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
